U.S. market Open. Closes in 4 hours 54 minutes

IPHA | Innate Pharma S.A. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for IPHA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak.

Valuation (26%)

Company Industry
P/E Ratio (TTM) -3.71 -23.05
PEG Ratio (TTM) 0.05 15.47
P/S Ratio (TTM) 3.79 49.46
P/B Ratio (TTM) 4.39 18.87
P/FCF Ratio (TTM) -6.96 -3.27
Price to 5YR AVG Earnings Ratio -2.60 -3.55
Price to 5YR AVG FCF Ratio -3.32 -9.37

Profitability (0%)

Company Industry
ROA (TTM) -22.48% -5.14%
ROE (TTM) -84.40% 16.69%
Net Profit Margin (TTM) -100.78% -1,583.93%
ROIC 5YR AVG -80.24% 15.15%

Growth (17%)

4QTR AVG 3YR AVG 5YR AVG
EPS -132.39% -289.95% -169.00%
Revenue -28.02% -36.65% 40.89%
Net Income -134.23% -336.21% -196.77%
Cash Flow 30.60% -17.94% -11.31%

Health (35%)

Company Industry
Current Ratio (TTM) 2.92 6.13
Quick Ratio (TTM) 2.84 5.85
D/E Ratio (TTM) 1.21 -15.81
Interest Coverage (TTM) -25.54 -1.57
Piotroski F-Score 3 5
Altman Z-Score N/A 14.12
LTL to 5YR AVG FCF -0.73 0.17
Shares Outstanding Growth 5YR AVG 6.75% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙